Filing excerpt
The Company resubmitted its application seeking FDA approval for filling of the EYLEA HD pre-filled syringe ("PFS") at Catalent Indiana, where the FDA has recently conducted a site re-inspection. In addition, the FDA did not act by the April 2026 PDUFA date on the Company's regulatory application for a second contract manufacturer for the PFS; therefore, this application remains pending.